Literature DB >> 2913022

Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics.

L P Jetté1, F Lamothe.   

Abstract

Four hundred and sixty-eight strains of Streptococcus pneumoniae isolated from blood or normally sterile body fluids in 14 Quebec, Canada, hospitals between 1 July 1984 and 31 December 1986 were serotyped, their susceptibilities to antimicrobial agents were determined, and the laboratory data were correlated with the clinical information. The distribution pattern of the serogroups and serotypes was similar to that observed previously in Quebec and to that in other parts of Canada and in the United States. No regional variation was observed. The distribution of serogroups and serotypes was different in pediatric patients (less than 18 years old) when compared with that of adults (P less than 0.001). Overall, 94% of the strains were represented in 23-valent vaccine. The total mortality rate was 12.8% and increased with age: 1.6% in pediatric patients, 14.8% in patients 18 to 64 years old, and 31% in those greater than or equal to 65 years old (P less than 0.001). In patients 18 to 64 years old, the mortality rate was higher when an underlying condition that could have justified prior vaccination was present (P = 0.008). In patients greater than or equal to 65 years old, the mortality rates were similar in those with and those without underlying conditions, suggesting that vaccine use in all patients greater than or equal to 65 years old might be appropriate. Only six patients had received pneumococcal vaccine before infection. Only 15 strains (3.2%) were moderately susceptible or resistant to one or more of the antimicrobial agents tested. Six strains were moderately susceptible to penicillin G, and none was fully resistant.

Entities:  

Mesh:

Year:  1989        PMID: 2913022      PMCID: PMC267222          DOI: 10.1128/jcm.27.1.1-5.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Prevention of pneumococcal pneumonia by vaccination.

Authors:  R Austrian; R M Douglas; G Schiffman; A M Coetzee; H J Koornhof; S Hayden-Smith; R D Reid
Journal:  Trans Assoc Am Physicians       Date:  1976

2.  Emergence of multiply resistant pneumococci.

Authors:  M R Jacobs; H J Koornhof; R M Robins-Browne; C M Stevenson; Z A Vermaak; I Freiman; G B Miller; M A Witcomb; M Isaäcson; J I Ward; R Austrian
Journal:  N Engl J Med       Date:  1978-10-05       Impact factor: 91.245

3.  Detection and prevalence of pneumococci with increased resistance to penicillin.

Authors:  J M Dixon; A E Lipinski; M E Graham
Journal:  Can Med Assoc J       Date:  1977-11-19       Impact factor: 8.262

4.  Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era.

Authors:  M A Mufson; D M Kruss; R E Wasil; W I Metzger
Journal:  Arch Intern Med       Date:  1974-09

5.  Epidemiology of clinically significant isolates of Streptococcus pneumoniae in the United States.

Authors:  C V Broome; R R Facklam
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

6.  Pneumococcal bacteremia in infants and children: a ten-year experience at the Cook County Hospital with special reference to the pneumococcal serotypes isolated.

Authors:  N M Jacobs; S Lerdkachornsuk; W I Metzger
Journal:  Pediatrics       Date:  1979-09       Impact factor: 7.124

7.  Penicillin-insensitive pneumococci. Case report and review.

Authors:  G A Ahronheim; B Reich; M I Marks
Journal:  Am J Dis Child       Date:  1979-02

8.  Pneumococcal serotypes causing bacteremia and meningitis: relevance to composition of pneumococcal vaccine.

Authors:  J M Dixon; A E Lipinski
Journal:  Can Med Assoc J       Date:  1981-08-01       Impact factor: 8.262

9.  Pneumococcal disease in a medium-sized community in the United States.

Authors:  M A Mufson; G Oley; D Hughey
Journal:  JAMA       Date:  1982-09-24       Impact factor: 56.272

Review 10.  Antibiotic-resistant Streptococcus pneumoniae: clinical and epidemiologic aspects.

Authors:  J Ward
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr
View more
  20 in total

1.  Use of an oxacillin disk screening test for detection of penicillin- and ceftriaxone-resistant pneumococci.

Authors:  L P Jetté; C Sinave
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

2.  Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.

Authors:  J Gerber; A Smirnov; A Wellmer; J Ragheb; J Prange; E Schütz; K Wettich; S Kalich; R Nau
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens.

Authors:  R J Davidson; D E Low
Journal:  Can J Infect Dis       Date:  1999-03

4.  Activity of vancomycin, teicoplanin and cephalosporins against penicillin-susceptible and penicillin-intermediate Streptococcus pneumoniae.

Authors:  V G Loo; J Lavallée; D McAlear; H G Robson
Journal:  Can J Infect Dis       Date:  1995-03

5.  Reduced susceptibility to penicillin among pneumococci causing invasive infection in children - Canada, 1991 to 1998.

Authors:  D Scheifele; S Halperin; L Pelletier; J Talbot; M Lovgren; W Vaudry; T Jadavji; B Law; N Macdonald; R Gold; E Wang; E Mills; M Lebel; P Déry; R Morris
Journal:  Can J Infect Dis       Date:  2001-07

6.  Surveillance of invasive Streptococcus pneumoniae infection in the province of Quebec, Canada, from 1996 to 1998: serotype distribution, Antimicrobial susceptibility, and clinical characteristics.

Authors:  L P Jetté; G Delage; L Ringuette; R Allard; P De Wals ; F Lamothe; V Loo
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

7.  In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.

Authors:  D E Low; J de Azavedo; R Davidson
Journal:  Can J Infect Dis       Date:  1999-03

Review 8.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

Review 9.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

10.  The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine.

Authors:  Adrienne Morrow; Philippe De Wals; Geneviève Petit; Maryse Guay; Lonny James Erickson
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.